Navenibart (Plasma Kallikrein Inhibitor)

May 27, 2026 — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will present seven abstracts from its hereditary angioedema (HAE) portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul (June 12–15, 2026). Six posters will report new clinical trial and real-world outcomes for ORLADEYO® (berotralstat), BioCryst’s oral once-daily plasma kallikrein inhibitor for HAE prophylaxis in patients aged ≥2 years, including: Japanese real-world treatment outcomes and prior prophylaxis patterns; 48-week APeX-P pediatric (2 to <12 years) data on reductions in attacks requiring on-demand therapy or professional care; outcomes in patients switching from other long-term prophylaxis (including C1-INH deficiency and normal C1-INH subgroups); and reductions in healthcare resource utilization in adolescents. One poster will present ALPHA-STAR trial analyses for investigational navenibart (YTE-modified long-acting monoclonal antibody plasma kallikrein inhibitor) by baseline attack rate, BMI, and age. The presentations support BioCryst’s clinical and real-world evidence base for ORLADEYO and advancement of navenibart as a longer-interval prophylaxis candidate.